Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jul 15, 2019; 11(7): 509-517
Published online Jul 15, 2019. doi: 10.4251/wjgo.v11.i7.509
Utilizing gastric cancer organoids to assess tumor biology and personalize medicine
Miranda Lin, Mei Gao, Michael J Cavnar, Joseph Kim
Miranda Lin, Mei Gao, Michael J Cavnar, Joseph Kim, Department of Surgery, University of Kentucky, Lexington, KY 40536, United States
Author contributions: All authors contributed equally to conception and design of the study, drafting or making critical revisions to intellectual content in the manuscript, and final approval of the final version of the article.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Joseph Kim, FACS, MD, Surgical Oncologist, Department of Surgery, University of Kentucky, 800 Rose St., Lexington, KY 40536, United States.
Telephone: +1-859-3238920 Fax: +1-859-3236840
Received: February 23, 2019
Peer-review started: February 23, 2019
First decision: April 15, 2019
Revised: April 25, 2019
Accepted: June 12, 2019
Article in press: June 13, 2019
Published online: July 15, 2019
Core Tip

Core tip: Patient-derived organoids are three-dimensional models of human cancer useful for investigating tumor biology and drug discovery. There are now many reports on the utility of organoids in cancer research and personalized therapy. However, none focus on the use of organoid technology in improving outcomes for patients with gastric cancer (GC), which is one of the deadliest cancers worldwide. Our objective is to report the current progress in GC organoid technology in comparison to traditional cancer models and evaluate their potential role in informing personalized clinical decision making for patients with GC.